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Objective. We sought to determine if any histopathologic component of the pulmonary microcirculation can 
distinguish systemic sclerosis (SSc)- related pulmonary fibrosis (PF) with and without pulmonary hypertension (PH).
Methods. Two pulmonary pathologists blindly evaluated 360 histologic slides from lungs of 31 SSc- PF explants or 
autopsies with (n = 22) and without (n = 9) PH. The presence of abnormal small arteries, veins, and capillaries (pulmo-
nary microcirculation) was semiquantitatively assessed in areas of preserved lung architecture. Capillary proliferation 
(CP) within the alveolar walls was measured by its distribution, extent (CP % involvement), and maximum number of 
layers (maximum CP). These measures were then evaluated to determine the strength of their association with right 
heart catheterization–proven PH.
Results. Using consensus measures, all measures of CP were significantly associated with PH. Maximum CP had 
the strongest association with PH (P = 0.013; C statistic 0.869). Maximum CP 2 or more layers and CP % involve-
ment 10% or greater were the optimal thresholds that predicted PH, both with a sensitivity of 56% and specificity of 
91%. The CP was typically multifocal rather than focal or diffuse and was associated with a background pattern of 
usual interstitial pneumonia. There was a significant but weaker relationship between the presence of abnormal small 
arteries and veins and PH.
Conclusion. In the setting of advanced SSc- PF, the histopathologic feature of the pulmonary microcirculation 
best associated with PH was capillary proliferation in architecturally preserved lung areas.
INTRODUCTION
Pulmonary hypertension (PH) is an independent risk factor for 
mortality in the setting of systemic sclerosis (SSc)- related pulmo-
nary fibrosis (PF). A prior UK Registry reported a dismal 3- year sur-
vival of 28% for SSc- PF- PH in the modern treatment era (1). Fur-
thermore, the presence of PH, as compared to no PH, has been 
associated with a 5- fold increased mortality in SSc- PF (2). Inter-
estingly, although our group has reported improved transplant- 
free survival for SSc- PF- PH compared with historical cohorts (3), 
the results of pulmonary arterial hypertension (PAH)- specific ther-
apy in SSc- PF- PH have been largely disappointing (4).
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Although we know that the entire pulmonary microcirculation 
(small arteries, veins, and capillaries) may be affected in SSc- PAH 
(without PF) (5–7), the pulmonary microcirculation has not been 
systematically contrasted between SSc- PF with, as compared 
to without, PH. From our University of California, Los Angeles 
(UCLA) lung explant pathology experience, we have inciden-
tally noted capillary proliferation (CP) in areas of lung specifically 
without significant fibrosis in our SSc- PF cohort, a finding also 
previously reported in idiopathic PF (IPF). To our knowledge, CP 
has not been evaluated as a possible association with right heart 
catheterization (RHC)- proven PH, complicating PF. As such, and 
to better understand the PH phenotype complicating SSc- PF, we 
elected to evaluate the pathology of the pulmonary microcircula-
tion with a focus on the capillary bed. For purposes of this study, 
the pulmonary microcirculation was exclusively evaluated in areas 
of relatively nonfibrotic lung. In contrast to nonfibrotic lung, the 
vascular changes in areas of fibrosis are generally predictable and 
homogeneous (8,9). In addition, a focus on nonfibrotic lung allows 
for better recognition of vascular abnormalities that may otherwise 
be obscured by interstitial pneumonia.
We took advantage of the SSc- PF lung tissue repository at 
UCLA and sought to systematically characterize the pulmonary 
microcirculation, dichotomized by those with and without RHC- 
proven PH. We hypothesized that CP in architecturally preserved 
areas of advanced SSc- PF lung tissue would be the element of 
the pulmonary microcirculation most likely to differentiate the PH 
and non- PH subgroups.
MATERIALS AND METHODS
The UCLA Institutional Review Board approved the study 
(IRB#11- 003042- CR- 00002). We identified 31 cases of SSc- PF 
with available explanted (n = 22) or autopsy (n = 9) lung tissue 
between January 2003 and December 2012.
Data collection. Patient charts were retrospectively ana-
lyzed and data were collected, including demographics, pulmo-
nary hemodynamics, and pulmonary function testing.
Definition of CP. We defined CP as an abnormal prolifer-
ation of alveolar capillaries at least two layers thick (as previously 
characterized by Wagenvoort and colleagues; 10), in contrast to 
the normal alveolar- capillary architecture that consists of a single 
capillary lumen lined by endothelial cells. However, this definition 
of CP is broad and does not account for confounding factors that 
may include underlying structural abnormalities, artifacts of pro-
cessing, and/or tangential sectioning. Therefore, we only evalu-
ated areas of nonfibrotic lung that were appropriately sectioned 
and free of artifact, as determined by the judgement of the expert 
pulmonary pathologists. Areas deemed to be distorted by crush 
artifact, poor tissue processing, insufficient inflation, and vascular 
congestion were excluded. Areas of CP in other portions of the 
lung, such as airway walls and pleural tissue, were not included 
for analysis.
Definition of PH. PH was defined using the following 
hemodynamic criteria at RHC: a resting mean pulmonary artery 
pressure (mPAP) ≥25 mmHg, pulmonary artery wedge pressure 
<15 mmHg, and pulmonary vascular resistance >3 Wood units. 
The “SSc- PF without PH” classification required a normal mPAP 
(<25 mmHg) at both the screening RHC and the RHC done on the 
day of lung transplantation to ensure that PH had not developed 
during the period of active listing as previously reported (11). The 
reported pulmonary hemodynamics in Table 1 were obtained from 
the screening RHC for both patient groups.
Study design
Histopathologic evaluation. As per standard UCLA pro-
tocol for surgical and autopsy specimens, all lungs were inflated 
through the bronchi with 10% neutral buffered formalin. After fixa-
tion in formalin for at least 24 hours prior to sampling, at least two 
sections per lobe were sampled from central (hilar) and peripheral 
parenchyma. As per protocol, lung samples were taken from both 
macroscopically fibrotic and normal- appearing lung. After paraffin 
embedding, all tissue sections were stained with hematoxylin and 
eosin (H&E), and one to two representative blocks for each case 
were stained with combined Masson’s trichrome/elastin van  Gieson 
(TRI- EVG) and CD31 immunohistochemistry stains. The H&E stain 
provides standard light microscopy evaluation; the TRI- EVG stain 
is used for evaluation of arterial and venous intimal fibrosis (small- 
vessel vasculopathy); and CD31 stains vascular endothelium. For 
purposes of this study, a case report form (Supplemental Figure 
E1) was developed to systematically document the histologic fea-
tures of the pulmonary microcirculation in our SSc- PF cohort. CP 
is also a reported pathologic finding from severely congested lungs 
(12), usually in the setting of long- standing clinical left- sided con-
gestive heart failure, which, importantly, was not a feature in our 
SSc- PF cohort. A 1- hour comprehensive training session includ-
ing the pathologists and pulmonologist (Rajan Saggar) allowed for 
consistent methodologic consensus in reporting the presence and 
degree of abnormal alveolar capillary pathology.
A blinded evaluation was then performed by two senior 
pulmonary pathologists (MCF, WDW) with extensive surgical 
and autopsy pathology experience. Each pathologist evalu-
ated 360 stained slides (324 histology slides [H&E or TRI- EVG] 
and 36 immunohistochemistry slides [CD31]). Each patient had 
between 6 and 18 slides, with a median of 11 slides per patient. 
The pathology evaluation was limited to only those areas of lung 
with preserved architecture (eg, areas of parenchyma where the 
architecture was not obscured or effaced by fibrosis. CP was 
assessed as a binary variable (yes/no) after review of all histol-
ogy slides for a given patient. If present, the distribution of CP 
was noted as focal, multifocal, or diffuse. The maximum CP (ie, 
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Table 1. Baseline demographics, pulmonary and systemic hemodynamics, and pulmonary function of a systemic sclerosis–related pulmonary 
fibrosis cohort divided into subgroups either with pulmonary hypertension or without pulmonary hypertension
 Total (n = 31) With PH (n = 22) No PH (n = 9) P Value
Tissue Type 0.029
Autopsy 9 (30.0%) 9 (40.9%) 0  
Transplant 22 (70.0%) 13 (59.1%) 9 (100%)  
Age at tissue acquisition (y) 0.071
Mean (SD) 53.6 (11.5) 56.0 (10.3) 47.8 (12.6)  
Median (Q1- Q3) 55.0 (48.5- 60.0) 55.0 (49.0- 63.8) 50.0 (33.0- 58.0)  
Gender 0.042
Female 19 (61.3%) 12 (54.5%) 7 (77.8%)  
Male 12 (38.7%) 10 (45.5%) 2 (22.2%)  
Time from right heart  
catheterization to tissue  
acquisition (d)
0.056
Mean (SD) 379.7 (428.1) 286.5 (391.0) 607.6 (451.1)  
Median (Q1- Q3) 168.0 (39.0- 718.5) 152.0 (33.5- 232.0) 771.0 (90.0- 956.0)  
Body mass index (kg/m2) 0.886
Mean (SD) 23.3 (3.7) 23.2 (4.0) 23.4 (3.1)  
Median (Q1- Q3) 23.0 (21.0- 25.5) 23.0 (21.0- 24.8) 22.0 (21.026.0)  
Systemic mean arterial  
pressure (mmHg)
0.612
Mean (SD) 86.4 (13.1) 87.1 (13.2) 84.4 (13.6)  
Median (Q1- Q3) 84.0 (76.5- 93.0) 85.0 (76.2- 97.5) 79.0 (77.0- 90.0)  
Heart rate (beats/min) 0.237
Mean (SD) 88.4 (14.4) 86.4 (14.7) 93.2 (13.2)  
Median (Q1- Q3) 88.0 (77.0- 96.0) 82.5 (77.0- 94.5) 91.0 (88.0- 102.0)  
Right atrial pressure (mmHg) 0.007
Mean (SD) 9.9 (6.6) 11.9 (6.8) 5.1 (2.2)  
Median (Q1- Q3) 8.0 (5.5- 12.5) 11.5 (7.2- 14.5) 5.0 (5.0- 7.0)  
Mean pulmonary artery  
pressure (mmHg)
<0.001
Mean (SD) 39.1 (15.6) 47.9 (8.1) 17.7 (3.0)  
Median (Q1- Q3) 43.3 (22.5- 51.0) 47.5 (42.6- 53.2) 17.3 (15.7- 17.7)  
Pulmonary artery wedge  
pressure (mmHg)
0.125
Mean (SD) 10.1 (4.0) 10.8 (3.8) 8.3 (4.3)  
Median (Q1- Q3) 10.0 (7.0- 13.5) 10.5 (7.2- 13.8) 6.0 (5.0- 11.0)  
Cardiac index (L/min/m2) 0.003
Mean (SD) 2.6 (0.8) 2.4 (0.8) 3.3 (0.6)  
Median (Q1- Q3) 2.4 (2.1- 3.0) 2.2 (1.8- 2.5) 3.2 (3.0- 3.7)  
Pulmonary vascular  
resistance (Wood units)
<0.001
Mean (SD) 7.4 (5.0) 9.8 (3.9) 1.7 (0.6)  
Median (Q1- Q3) 7.8 (2.3- 11.6) 9.1 (7.1- 12.7) 1.7 (1.5- 1.9)  
Forced vital capacity (L) 0.019
Mean (SD) 1.7 (0.6) 1.9 (0.6) 1.3 (0.4)  
Median (Q1- Q3) 1.5 (1.3- 2.0) 1.8 (1.4- 2.1) 1.2 (1.2- 1.3)  
Missing 1 1 0  
(continued)
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maximum number of layers) was reported for each slide relevant 
to each patient. Similarly, the extent of CP was reported for each 
slide and reflected the percentage of architecturally preserved 
lung area (nearest decile; Supplemental Figure E1) estimated to 
be occupied by CP.
Given that all subjects had a clinical diagnosis of PF, the 
blinded pathologists reported the major histologic fibrosis subtype 
(13) after review of all slides relevant to each patient as one of the 
following: usual interstitial pneumonia (UIP); nonspecific interstitial 
pneumonia (NSIP); a combination of UIP and NSIP; pulmonary 
veno- occlusive disease (PVOD); or other.
We attempted to distinguish arteries from veins based on ana-
tomic location in accordance with topographic guidelines described 
by the Development and Pathology Working group (14) (see sup-
plement: Histopathologic evaluation). However, despite adhering 
to these guidelines and focusing in areas of nonfibrotic lung, there 
was poor interpathologist reliability for the presence and extent of 
abnormal small arteries and veins (Supplemental Tables E2-E5). In 
light of this finding, we elected to analyze and report abnormal small 
arteries and veins collectively as a single category termed “small- 
vessel vasculopathy.”
Finally, the blinded pathologists were asked to comment on 
the presence or absence of hemosiderin- laden macrophages 
after reviewing all slides relevant to a particular patient.
Scanning electron microscopy evaluation. After the 
study period, one SSc- PF- PH subject underwent a limited tho-
racic autopsy 15 hours after sudden death. The lung specimen 
was prepared for scanning electron microscopy (SEM) and light 
microscopy. A previously published SEM image (15) demon-
strating normal pulmonary microvasculature and capillary bed is 
shown for comparison.
Sequential SSc- PF histopathology associated with 
the interval development of pulmonary hypertension. 
A surgical lung biopsy specimen was accessible from a single 
patient who had developed PH in the time between the surgical 
lung biopsy and lung transplantation. The pathology at the two 
Forced vital capacity  
(% predicted)
0.04
Mean (SD) 45.5 (15.9) 49.3 (15.9) 36.4 (12.5)  
Median (Q1- Q3) 41.5 (34.5- 51.0) 43.0 (38.0- 55.0) 34.0 (28.0- 40.0)  
Missing 1 1 0  
Forced expiratory volume,  
1 s (L)
0.004
Mean (SD) 1.4 (0.6) 1.6 (0.6) 0.9 (0.2)  
Median (Q1- Q3) 1.2 (1.0- 1.6) 1.5 (1.2- 1.8) 1.0 (0.9- 1.1)  
Missing 1 1 0  
Forced expiratory volume,  
1 s (% predicted)
0.003
Mean (SD) 46.8 (18.4) 53.0 (18.1) 32.3 (8.9)  
Median (Q1- Q3) 45.5 (32.5- 54.5) 50.0 (41.0- 56.0) 32.0(26.0- 36.0)  
Missing 1 1 0  
Diffusing capacity (ml/min  
per mmHg)
0.518
Mean (SD) 6.5 (4.1) 6.9 (4.7) 5.7 (2.3)  
Median (Q1- Q3) 5.7 (4.7- 7.4) 5.8 (4.9- 6.9) 4.8 (4.0- 7.6)  
Missing 3 2 1  
Diffusing capacity  
(% predicted)
0.337
Mean (SD) 24.9 (10.4) 23.7 (7.9) 27.8 (15.0)  
Median (Q1- Q3) 21.0 (20.0- 30.8) 21.0 (20.0- 28.0) 21.0 (17.0- 36.0)  
Missing 1 1 0  
Supplemental oxygen at  
tissue acquisition (L/min)
0.53
Mean (SD) 4.6 (3.2) 4.8 (3.2) 4.0 (3.3)  
Median (Q1- Q3) 4.0 (2.0- 6.0) 4.0 (3.2- 6.0) 2.0 (2.0- 5.0)  
Table 1. (Cont’d)
Total (n = 31) With PH (n = 22) No PH (n = 9) P Value
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time points was then compared specifically for CP in architectur-
ally preserved areas.
STATISTICAL ANALYSIS
Categorical variables were summarized using frequencies 
and percentages, whereas continuous variables were summa-
rized using means, standard deviations, and quartiles. Analysis of 
PH as an outcome was formulated as a logistic regression model. 
Consensus predictors were constructed to reconcile the different 
assessments by the two pathologists. For binary assessments, we 
compared consensus “yes” with consensus “no” valuations. After 
initial analysis of the data, we found poor interpathologist corre-
lations for identifying the presence and extent of abnormal small 
arteries and veins (Supplemental Tables E2-E5). As a result, we 
generated a single group termed “small- vessel vasculopathy” (rep-
resenting abnormal small arteries and veins) and analyzed the abil-
ity of the binary assessment to discriminate the PH and non- PH 
subgroups within the following patient- level score construct 
between the two pathologists: −1 points for consensus normal 
artery/vein; +1 points for consensus abnormal artery/vein; and 0 
points for discrepant artery/vein. As a result, the final patient- level 
score could range from −2 (consensus normal artery and vein) 
to +2 (consensus abnormal artery and vein). For median assess-
ments, we used the median of the two pathologists’ median 
assessments. For maximum assessments, we used the maximum 
of the two pathologists’ maximum assessments. Prediction of PH 
was also evaluated by adjusting for forced vital capacity (FVC) 
in order to evaluate pathologist assessment value- added. Other 
outcomes were analyzed using mixed effects logistic regression 
models. These models included random patient and pathologist 
effects in order to cluster different pathologists’ assessments of 
the same patient and different patient assessments by the same 
pathologist. All logistic regression models are summarized in terms 
of odds ratios and 95% confidence intervals (CIs). Classification 
accuracy of pathologist assessments was evaluated in terms of 
C- statistics. A C- statistic can be interpreted as the probability that 
a randomly selected event/case is given a higher score by the 
model than a randomly selected nonevent/control. A C- statistic 
close to 0.5 indicates that the model performs no better than ran-
dom noise in discriminating between cases and controls, whereas 
a C- statistic close to 1.0 indicates that the model provides perfect 
discrimination (16). Linear mixed effects models were summarized 
in terms of mean differences and 95% CI. Youden’s J- maximizing 
cutoffs for predicting PH were determined for all CP measures. P 
values less than 0.05 were considered statistically significant. All 
analyses were performed using SAS v.9.4 (SAS Institute Inc.).
RESULTS
Thirty- one SSc- PF patients were studied with lung pathol-
ogy obtained at autopsy (n = 9) or at lung transplantation (n = 
22) and were classified either with (n = 22) or without (n = 9) PH 
based on the cardiac catheterization data. There were a total of 
360 stained (324 H&E and TRI- EVG; 36 CD31) histopathology 
slides (226 with PH; 98 without PH) reviewed by two pathologists. 
Six to 18 slides were analyzed for each patient (median 11 slides 
per patient). Subjects with PH had increased FVC% predicted (49 
± 16 versus 36 ± 13; P = 0.04) and forced expiratory volume in a 
second percentage predicted (53 ± 18 versus 32 ± 9; P = 0.003) 
compared with those without PH. The PH group had an mPAP of 
48 ± 8 versus 18 ± 3 mmHg. Other baseline variables between 
the subgroups, including demographics, pulmonary and systemic 
hemodynamics, and pulmonary function, are reported in Table 1.
Pulmonary microcirculation changes associated 
with pulmonary hypertension
The interpathologist reliability was significant for the pres-
ence of CP (P < 0.001) with κ- statistic (95% CI) of 0.69 (0.41, 
0.97). Similarly, the interpathologist reliability by Spearman 
Table 2. C- statistics for models predicting pulmonary hypertension 
(PH) in terms of pathologist consensus measures and measures of 
capillary proliferation from a systemic sclerosis–related pulmonary 
fibrosis cohort stratified by the presence or absence of PH (based on 
the analysis of 324 pathology slides by two pathologists)
Effect C- Statistic P value
Consensus CP vs. consensus 
non- CP
0.753 0.011
Maximum CP median 0.869 0.013
Maximum CP maximum 0.821 0.011
CP % involvement median 0.838 0.027
CP % involvement maximum 0.737 0.029
Consensus NSIP (NSIP alone or 
NSIP + UIP) vs. consensus 
non- NSIP (only UIP)
0.558 0.651
Consensus small- vessel vasculopa-
thy vs. consensus non–small- 
vessel vasculopathy
0.720 0.029
 
PH No PH
P Value(n = 452) (n = 196)
Maximum CP   0.001
Mean (SD) 3.12 (1.92) 1.38 (0.84)  
Median (Q1, Q3) 3 (1, 4) 1 (1, 1)  
Min, Max 1, 10 1, 5  
Missing 128 50  
CP% Involvement    
Mean (SD) 3.21 (3.01) 0.66 (1.76) 0.006
Median (Q1, Q3) 3 (0, 5) 0 (0, 0)  
Min, Max 0, 11 0, 9  
Missing 127 50  
Abbreviation: CP, capillary proliferation; NSIP, nonspecific intersti-
tial pneumonia; UIP, usual interstitial pneumonia.
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 correlation for maximum CP and CP% involvement was 0.74 
and 0.75, respectively (Supplement E1A and B). As a consensus 
binary measure, CP was associated with PH (P = 0.01; C- statis-
tic 0.75). All measures of CP, including maximum CP and CP % 
involvement, were significantly associated with PH with C- sta-
tistic values that were 0.74 or greater (Table 2). Maximum CP 
median (the median of the two pathologists’ maximum assess-
ments of CP) was the CP measure most strongly associated 
with PH (P = 0.01; C- statistic 0.87). A maximum CP maximum 
of at least two layers and CP% involvement maximum of at least 
10% were optimal thresholds for predicting PH, both with a sen-
sitivity of 56% and a specificity of 91% (Supplemental Table E6). 
The maximum CP (mean ± SD layers) for the PH group, com-
pared with the group without PH, was 3.1 (1.9) and 1.4 (0.8) 
(P = 0.001) and, similarly, CP% involvement (based on decile) 
was 3.2 (3.0) and 0.7 (1.8) (P = 0.006), respectively (Table 2). 
The associations between all measures of CP and PH remained 
significant when adjusted for FVC, supporting the concept that 
the degree of lung fibrosis did not significantly contribute to 
these findings (Supplement Table E7). Figure 1 shows the histo-
logic features of CP typically seen in the SSc- PF- PH subgroup. 
H&E images (Figure 1A and B) show lung parenchyma with no 
interstitial fibrosis but with areas of CP that demonstrate mul-
tiple congested lumens, which are haphazardly oriented, with 
few areas of adjacent normal alveolar capillary architecture. The 
CD31 stain (Figure 1C) demonstrates alveolar wall capillary dila-
tation and proliferation.
As a consensus binary measure, small- vessel vasculopathy 
(presence of abnormal arteries and/or veins) was associated with 
PH (P = 0.03; C- statistic 0.72), although with a lower C- statistic than 
any CP parameter (Table 2). Finally, the presence of hemosiderin- 
laden macrophages trended to an association with PH (P = 0.06).
Relationship of CP to the remaining pulmonary 
microcirculation
As a consensus binary measure, small- vessel vasculopathy 
was associated with CP as a consensus binary measure (P = 
0.04), maximum CP median (P < 0.05), and CP% involvement 
maximum (P = 0.04) (Table 3).
Relationship of CP to the pattern of PF
More CP was seen in the UIP pattern of background PF. 
Compared with NSIP and combined UIP/NSIP, three of the four 
CP measures were significantly associated with a background of 
isolated UIP (maximum CP median, CP% involvement maximum, 
and CP% involvement median) (Supplement Table E8).
Figure 1. Typical capillary proliferation (CP) and small- vessel vasculopathy in lungs with advanced systemic sclerosis–related pulmonary 
fibrosis. (A) Diffuse distribution of CP (hematoxylin and eosin [H&E] stain; original magnification ×100); (B) Higher power example of CP; 
the alveolar walls have irregularly dilated capillaries with more than two layers (arrows) (H&E stain; original magnification ×200); (C) CP is 
demonstrated by highlighting endothelial cells, (CD31 immunohistochemistry stain; original magnification ×200); (D) Bronchovascular bundle 
demonstrating prominent pulmonary arterial intimal fibrosis (trichrome/elastin stain; original magnification ×100).
A B
C D
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SEM and sequential lung tissue analysis
Supplement Table E9 displays the pulmonary hemodynamics 
and pulmonary function testing for two additional SSc- PF sub-
jects, one SSc- PF- PH with SEM (autopsy) images (Supplement 
Table E9A), and another with sequential lung histopathology (Sup-
plement Table E9B; initial surgical biopsy [PH absent] and sub-
sequent explant with the interval development of PH). Standard 
light microscopy and SEM performed on the autopsy SSc- PF 
lung with PH showed CP in areas of lung with preserved archi-
tecture (Figure 2A) and abnormal capillary bed morphology and 
ultrastructure by SEM (Figure 2B compared with normal SEM in 
Figure 2C), respectively. In addition, standard light microscopy on 
lung tissue obtained sequentially from another SSc- PF subject ini-
tially at surgical lung biopsy (SSc- PF without PH; Figure 3A and 
B) and subsequently at lung transplantation (SSc- PF with PH; Fig-
ure 3C and D) exhibit the interval development of CP associated 
with clinical PH.
DISCUSSION
This study systematically evaluated the pulmonary microcir-
culation, with a focus on abnormal capillary structure, in a well- 
characterized SSc- PF cohort with and without PH, as demon-
strated by RHC. We specifically sought to determine if CP could 
distinguish SSc- PF with and without PH. Importantly, we focused 
on the pathology of the pulmonary microcirculation only in areas 
with preserved lung architecture without significant interstitial 
fibrosis because fibrosis may obscure microcirculatory changes 
and/or affect morphology (9). Our main finding was that, com-
pared with small- vessel vasculopathy (abnormal small arteries 
and veins), CP was the histopathologic element of the pulmonary 
microcirculation most capable of distinguishing SSc- PF- PH from 
SSc- PF without PH.
The data were presented as consensus measures of two 
pathologists with good interpathologist reliability with regard to 
Table 3. Mixed effects ordinal logistic regression models of small- 
vessel vasculopathy in terms of capillary proliferation measures
Effect
Small- Vessel 
Vasculopathy OR (95% CI) P value
Maximum CP median 2.03 (1.00, 4.12) 0.049
Maximum CP 
maximum
1.44 (0.98, 2.12) 0.061
CP% involvement 
median
1.37 (0.95, 1.97) 0.094
CP% involvement 
maximum
1.32 (1.01, 1.72) 0.043
CP (yes/no) 7.47 (1.15, 48.37) 0.036
Abbreviation: CI, confidence interval; CP, capillary proliferation; 
OR, Odds Ratio.
Figure 2. Light microscopy evaluation of alveolar tissue from the systemic sclerosis–related pulmonary fibrosis–pulmonary hypertension (SSc- 
PF- PH) autopsy that demonstrates irregular alveolar wall capillary proliferation in areas without interstitial fibrosis: (A) capillary proliferation (asterisk) 
adjacent to normal artery (thick arrow) and normal alveolar capillaries (thin arrow) (hematoxylin and eosin [H&E] stain; original magnification ×200); 
(B) scanning electron microscopy (SEM) image of a vascular cast from the same SSc- PF- PH autopsy specimen highlighting extensive and 
crowded capillary duplication in the walls of two alveolar sacs. Note the abnormal pulmonary angiogenesis in the microvasculature with bulbous 
budding alternating with pinched areas in the alveolar capillary bed (SEM; original magnification ×569); (C) SEM of normal lung microvasculature 
and capillary bed. Note the much thinner capillary bed with more orderly arrangement of capillary architecture with few capillaries showing 
budding or abrupt termination of blind pouches (photos courtesy of Dr. Kazufumi Nakamura), (SEM, original magnification ×200.
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measures of CP. Although all CP parameters were significant, the 
maximum CP had the strongest association with PH (C- statis-
tic 0.87). The capillary changes were usually multifocal and were 
associated with the UIP pattern of background PF (as opposed to 
the NSIP pattern). Compared with the SSc- PF group without PH, 
the SSc- PF- PH group had, on average, three layers of capillaries 
(versus less than 1.4 layers) involving 20%- 30% (versus less than 
10%) of the examined architecturally preserved area. A maximum 
CP of at least two layers and CP% involvement of at least 10% 
were optimal thresholds for predicting PH, both with a sensitiv-
ity of 56% and a specificity of 91%. Small- vessel vasculopathy 
(abnormal small arteries and veins) had a significant but weaker 
association with PH when compared with CP.
In all cases, the areas of CP were readily identifiable with H&E 
staining alone after the pathologists were trained on the diagnos-
tic features of CP, and areas with architectural remodeling or arti-
fact were excluded. The CD31 stain helped to highlight the CP 
by staining endothelial cells in areas of interest (Figure 1C), but 
the distinctive features of CP demonstrated by H&E, along with 
the nonspecific CD31 staining (including macrophages and larger 
vessels), limited the use of CD31 staining to evaluate CP in all 
cases. By delineating the intima between the endothelium and 
the elastic lamina, the TRI- EVG stain highlighted abnormal small 
artery and vein intimal fibrosis indicative of small vessel vascu-
lopathy (Figure 1D). However, despite distinct anatomic location 
differences (14) and a focus in areas of nonfibrotic lung, the patho-
logic distinction between abnormal small artery and vein was not 
always clear and suffered from poor interpathologist reliability. 
Consequently, we elected to report abnormal small arteries and 
veins collectively as a single category that we called “small- vessel 
vasculopathy.” Although small- vessel vasculopathy was found to 
be significantly associated with PH, this association was weaker 
when compared with CP. Ultimately, pathologic review of the alve-
olar capillary bed by routine H&E staining alone was reliable in dis-
tinguishing PH from non- PH clinical phenotypes. In our analysis, 
when PH complicates SSc- PF, the entire pulmonary microcircu-
lation is significantly abnormal, specifically in areas of nonfibrotic 
lung; however, the SSc- PF- PH phenotype is best distinguished 
from SSc- PF without PH by the increased presence and extent 
of CP.
The concept of vascular remodeling in PF was first 
 suggested by Turner- Warwick (17) in the form of systemic- 
to- pulmonary circulation neovascularization. Subsequently, 
human IPF lung homogenates have shown a  proangiogenesis 
Figure  3. (A) Alveolar tissue at surgical lung biopsy of a systemic sclerosis (SSc)–pulmonary fibrosis (PF) subject without pulmonary 
hypertension (PH) with normal and inconspicuous capillary architecture adjacent to area of interstitial pneumonia (hematoxylin and eosin stain 
[H&E]; original magnification ×100); (B) Higher- power view of alveolar tissue with normal architecture and inconspicuous capillaries (H&E stain; 
original magnification ×200); (C) Alveolar tissue from the same SSc- PF subject (hemodynamic data in Supplemental Table E9B) after the interval 
development of PH from explanted lung tissue in areas without interstitial pneumonia but with alveolar capillary prominence and proliferation 
(arrows) and venular fibrosis (star) (H&E stain; original magnification ×100); (D) Higher- power view of alveolar tissue from explant specimen 
showing alveolar capillary proliferation (arrows) (H&E stain; original magnification ×100).
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 signature (18), and in this context, alveolar capillaries have 
also demonstrated distinctly abnormal morphology based 
on SEM analysis in rats with bleomycin- induced PF (19). In 
human IPF, Ebina and coworkers (8) established an inverse 
relationship between the CD34+ alveolar capillary “vascular 
density” and the degree of pathologic fibrosis, with similar find-
ings described in SSc- PF human lung specimens (20). In a 
study of IPF, Colombat and coworkers studied the pulmonary 
microcirculation within areas of preserved lung architecture 
and reported significant panvascular pathology, including CP. 
Interestingly, they found no relationship between the presence 
of venopathy in architecturally preserved areas of IPF lung and 
RHC- determined PH; however, arteriopathy and CP were not 
evaluated in this context.
Abnormal capillary pathology has been reported in SSc and 
other connective tissue diseases (CTD) with PH without clinically 
significant fibrosis (5,15,16). Odronic and colleagues (6) reported 
four cases of pulmonary capillary hemangiomatosis (PCH)- like 
lesions in CTD- associated PAH, similar to the CP that we observed. 
Other reports describe a pattern of small- vessel vasculopathy and 
a lack of plexiform lesions as being unique to SSc- PAH (without 
PF), as compared with idiopathic PAH (15). A PVOD- like pattern 
and secondary capillary congestion has also been described in 
CTD- associated PAH (15,16). This capillary congestion is readily 
discernable from the CP that we report, although CP has been 
observed by SEM in clinical PVOD (26). It is also important to 
distinguish the CP that we report from the capillary congestion 
reported in long- standing pulmonary venous congestion (12). In 
this setting, capillary congestion causes an expansion of the lym-
phatics with dilated interseptal spaces, characteristics that we did 
not generally find or avoided by focusing on alveolar rather than 
lobular septal capillaries. In addition, none of our patients had the 
clinical picture of left heart failure.
The finding of CP and its association with PH also serves to 
increase the heterogeneity of abnormal pulmonary microcircula-
tion and, as a result, complicates the ability to predict the clini-
cal PH phenotype. For instance, it is generally accepted that in 
the context of clinical PVOD, as a consequence of downstream 
venous obstruction, capillaries may undergo angiogenesis, simi-
lar to the CP we report, and additional secondary changes can 
manifest, including mild PF (21). Alternatively, our data suggest 
that PF may similarly function as a primary trigger for CP (in a 
background of small- vessel vasculopathy) and associated PH, 
perhaps by providing the appropriate microenvironment favor-
ing angiogenesis (18,22). In consideration of this hypothesis, we 
demonstrated the interval development of CP (in a background of 
small- vessel vasculopathy) involving areas of architecturally pre-
served lung for the isolated SSc- PF subject in our cohort with 
accessible lung tissue, obtained before and after the development 
of RHC- proven PH. Our findings support the concept that within 
this panvasculopathy, CP had the best association with clinical 
PH in SSc- PF, whereas the presence of small- vessel vasculop-
athy (abnormal small arteries and veins) had a limited (inferior C- 
statistic), albeit significant, association with PH. Finally, the trend 
toward an increased presence of hemosiderin- laden macrophages 
in our SSc- PF- PH subgroup, a well- documented finding in pulmo-
nary vascular disease (21) as well as in PF with PH (21,22), further 
supports an abnormal capillary bed.
CP has also been shown in PH associated with congenital 
heart disease (23) and chronic thromboembolic disease (WHO 
Group 4: Chronic Thromboembolic Pulmonary Hypertension) 
(5). A focus on the capillary bed in the evaluation of pulmonary 
microcirculation pathology has recently gained attention and is 
timely, given the finding suggesting that only ~30% of the pulmo-
nary vascular resistance in PAH may be explained by the extent 
of  arteriopathy (24). Although this concept raises the question of 
arteriolar rarefaction as a contributing factor to elevated pulmo-
nary vascular resistance in PAH, abnormal capillary and venular 
pathology may also play a role, particularly in the setting of PH 
outside of WHO Group 1: Pulmonary Arterial Hypertension.
The cast vasculature seen in our SEM images of the PH lungs 
with what we have termed CP confirmed several haphazardly 
arranged layers in the alveolar walls. The capillaries had heteroge-
neous shapes, including irregular luminal diameter and budding, 
which suggests abnormal capillary neogenesis. These misshapen 
capillaries would not provide a clear pathway through the vascu-
lar bed and may contribute to increased vascular resistance. The 
lack of normal capillary structure would also affect both pulmonary 
hemodynamics and gas exchange. These abnormal capillaries 
have been reported in several conditions with a pathologic picture 
reminiscent of the PCH- PVOD spectrum of disease and are often 
associated with clinically progressive PH and hypoxemia (25–28).
CP has been reported to be a feature of architecturally pre-
served lung in the background of idiopathic UIP (9,29). Our study 
builds on this concept by reporting concordant findings in an 
SSc- PF cohort inherently at risk for UIP and/or NSIP (30). CP was 
significantly associated with a background of isolated UIP pathol-
ogy, as opposed to either NSIP or combined NSIP/UIP. Although 
the UIP fibrosis phenotype was not itself associated with PH in our 
study, we hypothesize that capillary rarefaction is likely greater in 
areas of UIP fibrosis compared with NSIP. If correct, the UIP fibro-
sis phenotype may be uniquely predisposed to angiogenesis and 
aberrant CP in areas of architecturally preserved lung and, in some 
cases, this progression may give rise to clinically significant PH.
There are several limitations to the study, including its retro-
spective study design and small sample size from a single insti-
tution. However, it is the largest SSc pathology cohort studied to 
date. It would have been ideal to include SSc- PAH without PF in 
our study; however, such tissue was simply unavailable as all of 
our SSc explants had significant PF. Surgical lung biopsies are 
uncommon in SSc lung disease because they rarely alter clini-
cal management; consequently, all pathology was obtained in the 
setting of advanced PF and results may not be generalizable to 
milder cases. Our pathologic assessments are semiquantitative, 
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but this limitation was mitigated by restricting pathologic evalua-
tion to experienced pulmonary pathologists practicing at a large 
lung transplant center. Furthermore, the pathologists met and 
agreed upon standards before any evaluations, and we used 
consensus statistical measures. Finally, there are limiting fac-
tors based on the pathology itself. Distinguishing small arteries 
and veins by light microscopy proved to be difficult in terms of 
interpathologist correlation despite the use of strict topographic 
criteria (31) when labeling vessels as arteries and veins, a focus 
in parenchymal areas not obscured by fibrosis, and the use of 
larger lung specimens to maximize the availability of such areas. 
Nevertheless, our analysis of the data combining abnormal small 
arteries and/or veins (small- vessel vasculopathy) provides more 
of a real- world pathology approach. The fibrosis and CP are a 
 heterogeneous process with great individual variation in the sever-
ity of the lesions and extent in different lungs. Even extensive sam-
pling may not give accurate representation of the full pathology, so 
no quantitative conclusions can be made. Finally, because the two 
SSc- PF subgroups were broadly separated with regard to pulmo-
nary hemodynamics and had minimal within- group variation, we 
chose not to define the correlation between pulmonary pressure 
(as a continuous variable) and CP.
We have demonstrated that CP in the architecturally pre-
served areas of patients with advanced SSc- PF is associated with 
PH, as determined by RHC. In the context of a panvasculopa-
thy, CP appears to be the element of the microcirculation most 
closely associated with PH. These data add to our understanding 
of the pathophysiology of PH in SSc- PF and suggest that aberrant 
capillaries and angiogenesis may be a major causative factor and 
future target for therapy in this population.
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